A61K 31/569
Substituted in position 17 alpha
Official title: substituted in position 17 alpha, e.g. ethisterone
A61K31/569 (Substituted in position 17 alpha) appears on 231 US grants and 324 published applications in this corpus.
Search patents in A61K- Granted patents
- 231
- Published applications
- 324
- Assignees
- 178
- Inventors
- 539
- Latest grant
- 21 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 4 | 0 |
| 1996 | 9 | 0 |
| 1997 | 9 | 0 |
| 1998 | 14 | 0 |
| 1999 | 13 | 0 |
| 2000 | 12 | 0 |
| 2001 | 3 | 4 |
| 2002 | 5 | 8 |
| 2003 | 4 | 7 |
| 2004 | 3 | 13 |
| 2005 | 2 | 11 |
| 2006 | 1 | 5 |
| 2007 | 2 | 8 |
| 2008 | 2 | 6 |
| 2009 | 1 | 5 |
| 2010 | 1 | 13 |
| 2011 | 6 | 9 |
| 2012 | 2 | 9 |
| 2013 | 4 | 15 |
| 2014 | 7 | 19 |
| 2015 | 8 | 20 |
| 2016 | 14 | 18 |
| 2017 | 11 | 22 |
| 2018 | 13 | 14 |
| 2019 | 9 | 18 |
| 2020 | 17 | 16 |
| 2021 | 11 | 22 |
| 2022 | 8 | 15 |
| 2023 | 11 | 18 |
| 2024 | 14 | 14 |
| 2025 | 5 | 8 |
| 2026 | 3 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating or preventing asthma by administering an IL-4R antagonist21 Jul 2026US 12,685,771 B2Regeneron Pharmaceuticals, Inc.
- Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists, androgen deprivation therapy and anti-androgen receptor therapy9 Jun 2026US 12,648,951 B2The University of Chicago
- Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions12 May 2026US 12,622,872 B2Nicox Ophthalmics, Inc.
- Methods of reducing mammographic breast density and/or breast cancer risk12 Aug 2025US 12,383,563 B2Havah Therapeutics Pty Ltd.
- Device for internal and external nasal application5 Aug 2025US 12,377,075 B2Haleon Ch Sarl
- Methods for treating or preventing asthma by administering an il-4r antagonist8 Oct 2026US 2026/0306627 A1Regeneron Pharmaceuticals, Inc.
- Cdk inhibitor and crystal form of pharmaceutically acceptable salt thereof, and use thereof24 Sep 2026US 2026/0285879 A1CSPC Ouyi Pharmaceutical Co., Ltd
- Methods for treating or preventing asthma by administering an il-4r antagonist25 Jun 2026US 2026/0174848 A1Regeneron Pharmaceuticals, Inc.
- Orally administered corticosteroid compositions26 Mar 2026US 2026/0083668 A1Ellodi Pharmaceuticals, L.P.
- Eutectic solvents comprising pharmaceutical agents, and methods of making and use thereof19 Feb 2026US 2026/0048009 A1Novilla Pharmaceuticals, Inc.
Most cited
By later US patents
- Drug delivery compositions for improved stability of steroids135US 5,780,050 ATheratech, Inc. · 1998
- Controlled release systems and low dose androgens123US 5,434,146 AEndorecherche, Inc. · 1995
- Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen107US 5,876,746 ACygnus, Inc. · 1999
- Skin permeation enhancer composition for use with sex steroids106US 5,693,335 ACygnus, Inc. · 1997
- Controlled release systems and low dose androgens93US 5,861,387 AEndorecherche, Inc. · 1999